---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-280159"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T02:43:57.431513+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# INOVIO Q3 net loss narrows to $0.15/sh; cash runway into Q1 2025

## Summary
- Q3 2022 revenue of $9.2M vs $292K in Q3 2021, driven by DoD contract.
- Net loss $37.8M ($0.15/sh) vs $60.2M ($0.29/sh) prior year; OpEx down to $44.9M.
- Cash and investments $281.9M; guidance extended to early 2025 with ~$45M Q4 cash burn.
- Discontinued internal INO-4800 heterologous COVID-19 booster; redeploying savings to other programs.
- Positive interim INO-3107 data: median 3 fewer RRP surgeries; 29% needed no intervention in 52 weeks.

## SEC filing metadata
- accession: 0001193125-22-280159
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312522280159/0001193125-22-280159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312522280159/d280542d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-280159
- JSON: https://secwatch.observer/filing/0001193125-22-280159.json
- Plain text: https://secwatch.observer/filing/0001193125-22-280159.txt

## Key facts
- Earnings Releases
  INOVIO PHARMACEUTICALS, INC. reported third quarter and nine months ended September 30, 2022 results: revenue $9.2 million, net income $37.8 million, or $0.15 per basic and diluted share, EPS $0.15 per basic and diluted share.
  - Period: third quarter and nine months ended September 30, 2022
  - Revenue: $9.2 million
  - Net income: $37.8 million, or $0.15 per basic and diluted share
  - EPS: $0.15 per basic and diluted share
  - Result: reported results
  source text: vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. INOVIO reported total revenue of $9.2 million for the three months ended, September 30, 2022, compared to $292,000 for the same period in 2021. The increase in revenue resulted from the fulfillment of obligations under its
  evidence_url: https://www.sec.gov/Archives/edgar/data/1055726/000119312522280159/0001193125-22-280159-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.